Blog
RSS FeedPosted by Michael Wonder on 12 Jul 2019
Aimmune statement on ICER final report on AR101 for peanut allergy
11 July 2019 - Exclusion of long-term desensitization and patient quality-of-life data by ICER fails to recognize the full value AR101 ...
Posted by Michael Wonder on 11 Jul 2019
ICER publishes evidence report on treatments for Duchenne muscular dystrophy
11 July 2019 - No price can be suggested as a fair value-based price for eteplirsen or golodirsen because no persuasive ...
Posted by Michael Wonder on 10 Jul 2019
ICER's final report on peanut allergy treatments: clinical evidence does not yet demonstrate that long-term benefits of desensitisation outweigh short-term risks
10 July 2019 - Independent appraisal committee highlights importance of non-clinical benefits and contextual considerations when evaluating AR101 and Viaskin Peanut. ...
Posted by Michael Wonder on 09 Jul 2019
Institute for Clinical and Economic Review lists potential topics for assessments in 2020
9 July 2019 - The Institute for Clinical and Economic Review has released its preliminary list of potential assessment topics ...
Posted by Michael Wonder on 29 Jun 2019
ICER posts draft scoping document for the assessment of treatments for acute migraine
28 June 2019 - Document open to public comment until 19 July 2019 ...
Posted by Michael Wonder on 24 Jun 2019
It’s Pioneer Institute vs. ICER: drug-pricing watchdog comes under fire for a ‘one-size-fits-all’ approach
24 June 2019 - An influential Boston-based watchdog group uses a “one-size-fits-all” approach to judge a fair price for prescription ...
Posted by Michael Wonder on 21 Jun 2019
U.S. group says Novartis MS drug price out of line with benefit
21 June 2019 - A U.S. group that reviews the value of medicines issued a critical report on Novartis’s new ...
Posted by Michael Wonder on 20 Jun 2019
Novel approaches to value assessment within the cost-effectiveness framework
20 June 2019 - The second plenary session focused on the need to move beyond conventional cost-effectiveness analysis of healthcare interventions ...
Posted by Michael Wonder on 20 Jun 2019
ICER issues final report and policy recommendations on esketamine for treatment-resistant depression
20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical benefits of esketamine versus placebo, ...
Posted by Michael Wonder on 20 Jun 2019
Institute for Clinical and Economic Review issues final report and policy recommendations on siponimod for secondary progressive multiple sclerosis
20 June 2019 - Independent appraisal committee votes that evidence is adequate to demonstrate siponimod offers superior effectiveness for patients ...
Posted by Michael Wonder on 20 Jun 2019
Boston drug pricing watchdog group has pharma companies’ attention
19 June 2019 - His adversaries call him a shill for health insurers, a bloodless bean counter who would rather ...
Posted by Michael Wonder on 18 Jun 2019
Zolgensma: a remarkable new treatment, an ICER analysis, and a poorly justified price
18 June 2019 - Defects in both sets of alleles in the coding region for the survival motor neuron 1 ...
Posted by Michael Wonder on 15 Jun 2019
Asthma and Allergy Foundation of America elevates patient voice in ICER review of new peanut allergy treatments
14 June 2019 - On June 11 in Oakland, CA the Institute for Clinical and Economic Review and its California Technology ...
Posted by Michael Wonder on 15 Jun 2019
New cost-effectiveness methods to determine value-based prices for potential cures: what are the options?
12 June 2019 - Evaluating different approaches to assessing the clinical effectiveness and value of potential cures will be essential to ...
Posted by Michael Wonder on 13 Jun 2019
Aimmune wins over ICER for peanut allergy product
12 June 2019 - Analysts predict blockbuster status for first-in-class. ...